Sera Prognostics (NASDAQ:SERA) Shares Down 3.6% – Should You Sell?

Shares of Sera Prognostics, Inc. (NASDAQ:SERA) were down 3.6% during mid-day trading on Thursday . The stock traded as low as $2.96 and last traded at $2.98. Approximately 25,728 shares changed hands during trading, a decline of 28% from the average daily volume of 35,732 shares. The stock had previously closed at $3.09.

Analysts Set New Price Targets

A number of research firms have recently commented on SERA. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday. Wall Street Zen upgraded shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Sera Prognostics Stock Performance

The stock has a market cap of $115.03 million, a price-to-earnings ratio of -3.87 and a beta of 0.97. The business’s 50 day moving average is $3.17 and its 200 day moving average is $2.75.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.03. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.10 million. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. Research analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Insider Transactions at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 21,158 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total value of $66,647.70. Following the completion of the sale, the chief executive officer directly owned 811,136 shares of the company’s stock, valued at approximately $2,555,078.40. This represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders sold 46,933 shares of company stock valued at $147,672. 13.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sera Prognostics

A number of large investors have recently made changes to their positions in the business. Lido Advisors LLC acquired a new stake in shares of Sera Prognostics during the third quarter worth approximately $68,000. Citadel Advisors LLC increased its stake in Sera Prognostics by 1.9% in the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after buying an additional 12,439 shares during the period. Two Sigma Investments LP purchased a new stake in Sera Prognostics in the 3rd quarter worth approximately $97,000. Squarepoint Ops LLC boosted its stake in shares of Sera Prognostics by 8.9% during the 3rd quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock valued at $285,000 after buying an additional 7,643 shares during the period. Finally, Balentine LLC acquired a new stake in shares of Sera Prognostics during the 3rd quarter valued at $258,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.